AstraZeneca Sees Potential for AI Beyond Drug Discovery

Dow Jones

07/27

1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.K. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 27, 2026 08:50 ET (12:50 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2654048871"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654048871\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654048871?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654048871","market":"sh","top_or_hot":-1,"title":"AstraZeneca Sees Potential for AI Beyond Drug Discovery","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 08:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Sees Potential for AI Beyond Drug Discovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Sees Potential for AI Beyond Drug Discovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-27 20:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 08:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2654048871","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654048871","pubTimestamp":1785156600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.K. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%.  Dow Jones NewswiresJuly 27, 2026 08:50 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","ARTY":"ISHARES FUTURE AI & TECH ETF","QTOC":"Innovator Growth Accelerated Plus ETF - October","AZN":"阿斯利康","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","VTHR":"Vanguard Russell 3000 ETF","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","AIPO":"Defiance AI and Power Infrastructure ETF","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4007":"制药","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4588":"碎股","BK4568":"美国抗疫概念","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","AGIX":"通用人工智能 ETF-AGIX"},"translate_title":"阿斯利康看到了药物发现之外的人工智能潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZNH":0.6,"VTHR":1.5,"ARTY":1.5,"AIPO":1.5,"AGIX":1.5,"QTOC":1.5,"AZN":0.9,"CHAT":1.5},"content_text":"1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.K. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 27, 2026 08:50 ET (12:50 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}